Supporting this notion, a clinical trial using cord blood-derived CAR-NK cells for B-cell malignancies observed minimal elevation of CRS-associated inflammatory factors such as IL-6 and TNF-α, suggesting a potentially safer therapeutic approach (55). This evidence concerns the gene TNF and congenital rubella syndrome.